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and area under the curve (AUC) was evaluated. p<0.05 was considered
statistically signiﬁcant.
Results: In female subjects, uCTX-II values signiﬁcantly increased according
to the severity of knee OA (Fig.1A). In male subjects, OA G3,4 group had
signiﬁcantly higher uCTX-II values than G0,1 group or G2 group (Fig.1B).
ĂFig 1. Relationship between knee X-ray OA grades and uCTX-II levels in (A)
female and (B) male subjects. Each box represents the 25th/50th (median)
to 75th percentiles. The lines outside the box represent the 10th and 90 th
percentiles. *; P<0.05. **; P<0.01, ***; P<0.001.
The mean levels of uCTX-II in each quartile were 152, 236, 345, 554 ng/
mmol Cre in female and 121, 188, 269, 469 in male. Higher quartiles (Q3
and Q4) of uCTX-II level included higher numbers of OA (G2) subjects in
female but not signiﬁcant in male (Fig.2).
ĂFig. 2 Quartiles by uCTX-II levels and proportion of OA grades in (A) female
and (B) male. Each quartile has 65 and 69 subjects in female and mal-
e.Signiﬁcant difference was observed only in female (p<0.0001,Chi-square).
ROC curve analysis for discriminating G2 OA showed that AUC was 0.65
and 0.61 in female and male, respectively. If cut-off is 300 in female,
sensitivity and speciﬁcity are 60 and 65 %, respectively.
Conclusions: uCTX-II is more useful in female older than 60 years but
a modest biomarker of knee OA X-ray grade by the single measurement in
the cross-sectional study. OA changes of other joints (e.g. lumbar spon-
dylosis) may affect the level of uCTX-II. Further analysis of longitudinal
changes of uCTX-II and knee OA grade using the data of 2007 (5th) and
2010 surveys is in progress.
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PERFORMANCE METRICS OF A NEWLY FORMATTED TYPE II COLLAGEN
CLEAVAGE NEO-EPITOPE ASSAY FOR HUMAN URINE: C2C-HUSA
J.L. Huebner 1, N. Ha 2, S. Bourdon 2, V.B. Kraus 1. 1Duke Univ. Med. Ctr.,
Durham, NC; 2 IBEX Pharmaceuticals, Inc, Montreal, QC, Canada
Purpose: The purpose of this studywas to evaluate the performancemetrics
of a new C2C sandwich immunoassay (IB-C2C-HUSA), including reproduc-
ibility and linearity as well as variation due to physical activity or food
consumption, to inform biospecimen collection protocols in clinical trials.
Type II collagen is themost abundant collagen inarticular cartilage, providing
tensile strength, and is cleaved by collagenases, resulting in the creation of
a neoepitope at the C terminus of the 3/4 length fragment, detectable in
human body ﬂuids by the C2C competitive ELISA. Once this initial cleavage
has occurred, proteases create subsequent degradation products containing
the C-terminal neoepitope that are detectable in human urine.
Methods: Forty participants with knee OA (20 patients for each of two
cohorts) were admitted overnight for serial urine sampling to assess the
variation of OA-related biomarkers. Urine samples were obtained on theevening (6-8PM) of Day 1 (T3; n¼34), prior to rising (8AM) from bed (T0;
n¼34), 1 hr after rising (9AM) without food consumption (T1a; n¼20), 1-2
hr after rising (9-10AM) with food consumption (T1; n¼34), and at noon, 4
hr after rising (T2; n¼14). Urine C2C was measured using the new IB-C2C-
HUSAand valueswere corrected for creatinine concentrations and reported
as ng/mmol Cr. The linearity of the assay was determined by testing each
urine sample at neat, 1:2, and 1:4 dilutions. The percent recovery was
calculated as the adjusted concentration versus the adjusted concentration
of the previous dilution. The acceptance criteria for linearity are between
70-130%. To assess for variation due to activity and food consumption across
the cohorts, the biomarker concentrations at each time point for each
subject were normalized to the mean concentration of the four time points
for that individual. Results were analyzed using non-parametric Friedman's
testwith Dunn's post-hocmultiple comparison test. To compare the results
of the newly formatted assay to the original C2C assay, correlation analyses
of the IB-C2C-HUSA toC2C valuesmeasuredpreviously in the same samples
was performed. Statistical analyses were performed using GraphPad soft-
ware and a p-value <0.05 was considered signiﬁcant.
Results: C2C was measurable in all urine samples using the new IB-C2C-
HUSA and values from analysis of neat samples were used for 98.5 percent
of the determinations. For samples that had concentrations higher than
the highest standard (5000 pg/ml), a dilution factor of 1:2 was used to
determine the ﬁnal concentration. The standard curve was linear
(R2¼0.992) and the assay was linear from neat to 1:4 dilutions with amean
percent recovery of 126%. The mean concentrations +SD and range for the
IB-C2C-HUSA biomarker at each time point (pg/ml) were as follows: T0:
1244+1055 (249-5246);T1a: 1635+1205 (344-5771); T1: 1871+1032 (443-
4952); T2: 1074+ (239-3213); T3: 1043+814 (240-3845). Whereas C2C
concentrations, uncorrected for urine creatinine, varied greatly within
a day (Fig 1A), C2C concentrations corrected for creatinine demonstrated
no statistically signiﬁcant variation of the biomarker with either activity
(T1a) or with food consumption (T1) (Fig 1B), the two conditions most
likely to affect sampling in a clinical trial. A comparison of values obtained
from the original C2C and the IB-C2C-HUSA assay at each time point
revealed a signiﬁcant correlation between the original and new formats for
T1a (p¼0.001, r2¼0.46), T1(p¼0.04, r2¼0.12) , and T2 (p¼0.03, r2¼0.33).
Conclusions: The new IB-C2C-HUSA immunoassay is a highly reproducible
sandwich assay that yielded measurable type II collagen neoepitope frag-
ments in all 136 samples tested. Compared with the original C2C compet-
itive ELISA, this new sandwich ELISA did not show variation due to activity.
This makes it useful for the measurement of collagen degradation in OA
studies, and in particular, it would be appropriate for analyses of legacy
samples, obtained without regard to standardization of time of collection.
Ă
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ELEVATED EXPRESSION OF MMP9 IN PLASMA OF PATIENTS WITH
SYMPTOMATIC KNEE OSTEOARTHRITIC: CORRELATION WITH DISEASE
SEVERITY AND PROGRESSION
M. Attur 1, J.D. Greenberg 1, J. Todd 2, Q.A. Lu 2, R. Ramirez 2, C. Oh 3,
J. Samuels 1, S. Krasnokutsky 1, S.B. Abramson 1. 1NYUHosp. for Joint
Diseases, New York, NY; 2 Singulex, Alameda, CA; 3NYU-Dept. of
Environmental Med., New York, NY, USA
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S87Purpose: Osteoarthritis is degenerative joint disease that leads to
permanent joint damage and is a multi-factorial complex disease. It is
well established that in OA cartilage and synovium that some of the
metalloproteinases (MMP) are over expressed including MMP- 2, 9 and
13 and Tissue inhibitors of Matrix metalloproteinases (TIMP) are down
regulated. There is currently great interest in the ﬁeld of OA to identify
biomarkers that provide a method for earlier diagnosis and identify
patients at higher risk for disease progression. This study was designed
to test the hypothesis that plasma levels of gelatinase(s) MMP-2 and 9
predict knee OA severity and progression based on radiographic
ﬁndings.
Methods: 150 Symptomatic knee OA (SKOA) patients (mean age 63.09 
10.3, mean BMI 26.5  3.6) fulﬁlling ACR criteria for knee OA were
recruited as part of an NIH-funded 24 month prospective study. These
patients were followed longitudinally for 24 months, x-ray were taken at
visit 0 and 24 months. The blood samples were collected at baseline and
every 6 months. Standardized semi-ﬂexed radiographs were scored for
overall Kellgren and Lawrence (KL) grade, osteophytes, joint space width
(JSW) and subchondral sclerosis by the same radiologist. Plasma samples
from visit 18 month of 128 OA patients (37% male) were assayed for
gelatinase(s) MMP-2 and 9 using the highly sensitive Erenna Immunoassay
system (Singulex, Inc). For radiographic severity, biomarker were evalu-
ated between KL scores of 1, 2 with those with scores of 3, 4. Progression of
knee OA was deﬁned as a change between baseline and 24 month visit in
narrowest joint space width (JSW) in signal knee.
Results: The mean plasma MMP2 and 9 (pro and total) levels were 83.0 
63.05 ng/ml, 30.7  32.64 and 455.9  290.09 (all ng/mL), respectively.
Only total MMP-9 positively correlated with KL score both at baseline
(r¼0.220; p<0.036) and 24 (r¼0.249; p<0.015) month. MMP-2 or
proMMP9 levels did not correlate with either radiographic marker. We
further analyzed association of tMMP9 level with radiographic severity
and progression by JSN as deﬁned in the methods. tMMP9 correlated with
radiographic severity (p<0.061) at baseline, and with progressive joint
space narrowing (r¼ 0.228; p<0.015). However, we did not observe
signiﬁcant association between tMMP9 and delta KL score in this 24month
study.
Conclusions: These ﬁndings indicate that elevated levels of total gelati-
nase -9 (tMMP9) are associated with radiographic severity of SKOA and
predict an increased risk of progressive joint space narrowing (JSN). These
observations, which suggest that tMMP9 is a candidate prognostic
biomarker, merit further validation in larger cohort of SKOA patients.160
STRUCTURAL PROGRESSION OF ANKYLOSING SPONDYLITIS IS
ASSOCIATED WITH ELEVATION IN TWO NOVEL, INFLAMMATORY
BIOMARKERS; MATRIX METALLOPROTEINASE AND CATHEPSIN-
DERIVED CRP
A.C. Bay-Jensen 1, H. Skjøt-Arkil 1, M.A. Karsdal 1, D.J. Leeming 1,
W.P. Maksymowych 2, S. Wichuk 2, P. Qvist 1. 1Nordic BioSci., Herlev,
Denmark; 2Univ. of Alberta, Div. of Rheumatology, Edmonton, AB, Canada
Purpose: Ankylosing Spondylitis (AS) is a chronic inﬂammatory disease,
however current inﬂammatory biomarkers, such as CRP, have insufﬁcient
sensitivity and speciﬁcity to be broadly accepted in the diagnosis and
prognosis of this disease. We hypothesized, that quantiﬁcation of inﬂam-
mation markers derived from the affected tissue might have improved
clinical utility compared to the systemic markers, and we therefore
developed two novel biomarker assays detecting MMP and Cathepsin-
derived CRP. Both CRP-MMP and CRP-CAT has been reported to be elevated
in AS compared to controls (Skjøt-Arkil et al., in print), whereas full-length
CRP was not.
The purpose of the present study was to determine, in a larger, second
cohort of patients with AS, the clinical utility of CRP-MMP and CRP-CAT
including (1) diagnostic sensitivity & speciﬁcity, (2) association with long-
term radiological changes in the spine (modiﬁed Stoke AS Spinal Score
(mSASSS)), and (3) sensitivity to anti-TNF treatment.
Methods: Cohort 1; Serum samples (n¼124) obtained from patients
diagnosed with AS was available for this study. Mean duration of diseasewas 18,0+11,4 years (mean+SD) and they had received 2.3+9.7 months of
anti-TNF treatment before study entry.
Within this cohort, samples from 16 AS patients with structural progres-
sion over two years and 29 without were selected for evaluation of the
prognostic value of the marker set (sub-cohort 1A). Structural progression
was achieved in subjects having a baseline mSASSS of at least 10 units
increasing with at least 5 units over two years, and simultaneously the
occurrence of at least one new syndesmophyte.
Sub-cohort 1B contained samples from 53 AS patients from cohort 1, and
these originated from patients who subsequently received anti-TNF
treatment for three months and was then re-tested with the marker panel.
Finally, we included serum samples (n¼40) from healthy subjects as
additional controls (Cohort 2).
Serum samples were tested for CRP-MMP and CRP-CAT (Nordic Bioscience,
Denmark).
Results: For baseline evaluations, data from cohort 1 and 2 were used.
CRP-MMP and CRP-CAT were both elevated in AS compared to controls;
9.84+4.40 ng/ml (mean+SD) vs 4.82+1.49 ng/ml (p<0.05), respectively, for
CRP-MMP; and 299.6+137.6 ng/ml vs 178.6+54.03 ng/ml (p<0.05), for CRP-
MMP. Diagnostic capability was assessed by ROC analysis, and AUC was
0.94 (p<0.0001) and 0.85 (p<0.0001) for CRP-MMP and CRP-CAT,
respectively.
In AS patients with structural progression over two years (sub-cohort 1A),
CRP-MMP and CRP-CAT were signiﬁcantly elevated at baseline compared
to non-progressors, whereas hsCRP was not; 9.2+3.1 ng/ml vs 7.6+2.2 ng/
ml for CRP-MMP, 276+108 ng/ml vs 218+67 ng/ml for CRP-CAT, and
21.9+25.6 ng/ml vs 12.7+21.5 ng/ml for hsCRP, respectively.
Finally, both CRP-related markers decreased signiﬁcantly after short term
(2-3 months) of anti-TNF treatment (sub-cohort 1B).
Conclusions: In a second, much larger cohort of AS patients, we have
conﬁrmed the original observation, that MMP and Cathepsin-derived
fragments of CRP, i.e. CRP-MMP and CRP-CAT, both are signiﬁcantly
elevated in AS patients. Importantly, both markers, but not hsCRP, were
signiﬁcantly elevated at baseline in patients having structural progression
deﬁned by a composite index including mSASSS and syndesmophyte
quantiﬁcation.
Further studies are needed to determine if the suggested association of the
two CRP-fragments with structural deterioration of AS reﬂects a metabolic
link to pathological processes in the spine.
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ADIPOKINES AND (VERY) EARLY-STAGE OSTEOARTHRITIS BURDEN AND
PROGRESSION OF KNEE AND HIP: DATA FROM CHECK
W.E. van Spil, N.W. Jansen, S.C. Mastbergen, J.W. Bijlsma, F.P. Lafeber. Univ.
Med. Ctr. Utrecht, Utrecht, Netherlands
Purpose: To investigate the potential relevance of adipokines in the
development and/or progression of (very) early knee and hip osteoarthritis
(OA).
Methods: Adipokine levels were related to serum and urinary biomarkers
of cartilage and synovial metabolism as well as radiographic OA burden
and 5-year progression
Baseline plasma leptin, adiponectin, and resistin levels were assessed by
ELISA in samples from CHECK (Cohort Hip & Cohort Knee), a prospective
cohort of 1002 individuals with symptoms of (very) early knee and/or hip
OA.
Baseline biomarkers of cartilage and synovial metabolism were assessed
by ELISA or RIA (Cartilage: uCTX-II, sPIIANP, sCS846. Synovial tissue: sHA,
sPIIINP. Cartilage/synovial tissue: sCOMP).
Knee and hip radiographs were obtained at baseline and after 2 and 5
years. OA burdenwas expressed as the summed Kellgren & Lawrence (K&L)
score for knees and hips at baseline. OA progression was expressed as the
area under the curve (AUC) of the summed K&L scores.
Associations were investigated through multiple linear regression and
binary logistic regression (OA burden: summed K&L grade 0 vs >1,
progression: AUC 0 vs >0).
Results: Data were complete for approximately 800 participants at base-
line and 725 participants at all time points. Baseline summed K&L grades 0,
1, 2, 3, and 4 were present in 33.9, 26.8, 24.0, 9.6, and 5.7% of participants,
respectively (maximum K&L grade for individual joints¼1). AUC of
